Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - furosemide (frusemide) -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - furosemide (frusemide) -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - furosemide (frusemide) -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - furosemide (frusemide) -

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - furosemide, quantity: 50 mg - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide; sodium chloride - oedema: furosemide-baxter injection is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. frusemide is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. furosemide-baxter injection is also indicated as adjunctive therapy in acute pulmonary oedema and cerebral oedema where intense and rapid onset is desired. if gastrointestinal absorption is impaired or oral medication is not practical for any reason, frusemide is indicated by the intravenous route. parenteral use should be replaced with oral frusemide as soon as practical.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - furosemide, quantity: 20 mg - injection, solution - excipient ingredients: sodium hydroxide; water for injections; sodium chloride; hydrochloric acid - oedema: furosemide-baxter injection is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. frusemide is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. furosemide-baxter injection is also indicated as adjunctive therapy in acute pulmonary oedema and cerebral oedema where intense and rapid onset is desired. if gastrointestinal absorption is impaired or oral medication is not practical for any reason, frusemide is indicated by the intravenous route. parenteral use should be replaced with oral frusemide as soon as practical.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - furosemide, quantity: 20 mg - tablet - excipient ingredients: magnesium stearate; sodium starch glycollate type a; pregelatinised maize starch; maize starch; lactose monohydrate - oedema frusemide is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. frusemide is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired.,parenteral therapy with frusemide should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. if gastrointestinal absorption is impaired or oral medication is not practical for any reason, frusemide is indicated by the intravenous or intramuscular route. parenteral use should be replaced with oral frusemide as soon as practical.,hypertension oral frusemide may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with frusemide alone.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - furosemide, quantity: 40 mg - tablet - excipient ingredients: sodium starch glycollate type a; maize starch; lactose monohydrate; magnesium stearate; pregelatinised maize starch - oedema frusemide is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. frusemide is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired.,parenteral therapy with frusemide should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. if gastrointestinal absorption is impaired or oral medication is not practical for any reason, frusemide is indicated by the intravenous or intramuscular route. parenteral use should be replaced with oral frusemide as soon as practical.,hypertension oral frusemide may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with frusemide alone.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - furosemide (frusemide) -

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - furosemide, quantity: 20 mg - tablet - excipient ingredients: pregelatinised maize starch; magnesium stearate; lactose monohydrate; sodium starch glycollate type a; maize starch - oedema frusemide is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease including the nephrotic syndrome. frusemide is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired.,parenteral therapy with frusemide should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. if gastrointestinal absorption is impaired or oral medication is not practical for any reason, frusemide is indicated by the intravenous or intramuscular route. parenteral use should be replaced with oral frusemide as soon as practical.,hypertension oral frusemide may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with frusemide alone.